

1                   **Activation of a *Vibrio cholerae* CBASS anti-phage system by**  
2                   **quorum sensing and folate depletion**  
3

4   **Geoffrey B. Severin<sup>1#</sup>, Miriam S. Ramliden<sup>2</sup>, Kathryne C. Ford<sup>3</sup>, Andrew J. Van Alst<sup>3</sup>, Ram**  
5   **Sanath-Kumar<sup>3</sup>, Kaitlin A. Decker<sup>3</sup>, Brian Y. Hsueh<sup>3</sup>, Soo Hun Yoon<sup>3</sup>, Lucas M. Demey<sup>3</sup>, Brendan**  
6   **J. O'Hara<sup>2</sup>, Christopher R. Rhoades<sup>3</sup>, Victor J. DiRita<sup>3</sup>, Wai-Leung Ng<sup>2</sup>, and Christopher M.**  
7   **Waters<sup>3\*</sup>**

8                   <sup>1</sup>Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing,  
9                   Michigan, USA, 48824

10                  <sup>2</sup>Department of Molecular Biology and Microbiology, Tufts University School of Medicine,  
11                  Boston, Massachusetts, USA

12                  <sup>3</sup>Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing,  
13                  Michigan, USA

14                  <sup>#</sup>Current Address, Department of Microbiology and Immunology, University of Michigan, Ann  
15                  Arbor, Michigan, USA

16

17                  **\*Corresponding Author:**

18                  5180 Biomedical and Physical Sciences

19                  567 Wilson Road

20                  East Lansing, MI 48824

21                  Telephone 517-884-5360

22 E-mail: [watersc3@msu.edu](mailto:watersc3@msu.edu)

23

24 Short title: Folate and QS regulation of CBASS

25 Key Words: cyclic GMP-AMP; CD-NTases; phage; quorum sensing; folate

26 Declarations of interest: none

27

28 **Abstract**

29 A major challenge faced by bacteria is infection by bacteriophage (phage). Abortive infection is  
30 one strategy for combating phage in which an infected cell kills itself to limit phage replication,  
31 thus protecting neighboring kin. One class of abortive infection systems is the cyclic  
32 oligonucleotide based anti-phage signaling system (CBASS) which relies on two core enzymatic  
33 activities; an oligo-nucleotide cyclase that is activated following phage infection and a cyclic-  
34 oligo-nucleotide sensitive effector whose activity kills the infected cell. However, the  
35 mechanisms behind the deployment and activation of these lethal CBASS systems prior-to and  
36 following infection have largely remained a mystery. While exploring unique genomic features  
37 of the current pandemic *Vibrio cholerae* biotype El Tor for clues underlying its pandemic success  
38 we found its CBASS was spuriously activated by the folate biosynthesis inhibitor  
39 sulfamethoxazole, but only after the population had reached a high-cell density. This population  
40 density dependent activity revealed that transcription of both the oligo-nucleotide cyclase,  
41 *dncV*, and the CBASS phospholipase effector, *capV*, is enhanced at high-cell density by quorum  
42 sensing. Together, these results demonstrate that the *V. cholerae* CBASS is deployed when the

43 environment is densely populated and activated in response to a perturbation in folate  
44 biosynthesis.

45

46 **Significance**

47 To counteract infection with phage, bacteria have evolved a myriad of molecular defense  
48 systems. Some of these systems initiate a process called abortive infection, in which the  
49 infected cell kills itself to prevent phage propagation. However, such systems must be inhibited  
50 in the absence of phage infection to prevent spurious death of the host. Here we show that the  
51 cyclic oligonucleotide based anti-phage signaling system (CBASS) accomplishes this by sensing  
52 intracellular folate molecules and only expressing this system in a group. These results enhance  
53 our understanding of the evolution of the 7<sup>th</sup> *V. cholerae* pandemic and more broadly how  
54 bacteria defend themselves against phage infection.

55

56 **Introduction**

57 The diarrheal disease cholera, caused by the Gram-negative bacterium *Vibrio cholerae*, is spread  
58 through consumption of contaminated food and water (1). Of the seven recorded cholera  
59 pandemics the classical biotype is believed to have caused at a minimum both the 5<sup>th</sup> (1881 -  
60 1896) and 6<sup>th</sup> (1899 - 1923) pandemics whereas the El Tor biotype is responsible for initiating  
61 and perpetuating the 7<sup>th</sup> pandemic (1961 - today) (2, 3). While strains of the classical biotype  
62 are now rarely encountered in environmental and clinical settings, numerous assays have been  
63 developed to help distinguish *V. cholerae* isolates as belonging to either the classical or El Tor  
64 biotypes (4, 5). These include disparate growth on citrate, hemolytic activity, casein proteolysis,

65 production of acidic or neutral byproducts from growth on glucose, differences in virulence  
66 gene allele sequences and expression, and disparate sensitivities to the cationic antimicrobial  
67 peptide polymyxin B and the folate biosynthesis inhibitor sulfamethoxazole (SMX).

68

69 Two of the largest genetic differences between the *V. cholerae* biotypes are the Vibrio Seventh  
70 Pandemic Islands 1 and 2 (VSP-1 and 2) genomic islands that are defining features of the El Tor  
71 biotype and absent in the classical biotype (3, 6, 7). VSP-1 and 2, which collectively contain ~36  
72 genes, are hypothesized to have played a critical role in the pandemic evolution of the El Tor  
73 biotype and many recent studies have begun to explore the biological functions they encode.

74 The predominant function of these islands appears to be protection against invasive biological  
75 elements as two phage defense systems, AvclD (8, 9) and a Type II cyclic oligonucleotide based  
76 anti-phage signaling system (CBASS) (10–13), are encoded on VSP-1 while VSP-2 encodes the  
77 *ddmABC* operon, which inhibits plasmid acquisition, plasmid stability, and phage invasion (14,  
78 15). In addition to biological defense, a three gene operon on VSP-2 that is encoded in some  
79 strains of El Tor mediates aerotaxis in response to zinc (16). Outside of these four systems, little  
80 is known of the function of the VSP islands or their contribution to the emergence of the El Tor  
81 biotype.

82

83 The VSP-1 CBASS encompasses a four gene operon [*vc0178(capV)*-*vc0179(dncV)*-*vc0180(cap2)*-  
84 *vc0181(cap3)*]. In this system, via an unknown mechanism, phage infection stimulates DncV, a  
85 member of the CD-NTase family of enzymes (17), to synthesize of 3'3' cyclic GMP-AMP (cGAMP)  
86 (11, 18). cGAMP then allosterically activates the phospholipase CapV, which rapidly degrades

87 the infected cell's own membrane (10). Cap2 enhances the production of cGAMP by post  
88 translationally modifying the C-terminus of DncV in a manner analogous to ubiquitination (12,  
89 13). Conversely, Cap3 suppresses DncV activity by precisely proteolyzing this same C-terminal  
90 modification (12, 13). Ultimately, activation of VSP-1 CBASS rapidly kills the infected cell to  
91 restrict phage propagation and protect neighboring kin from further phage predation, a  
92 mechanism called abortive infection (11). While CBASS systems are widely encoded in bacterial  
93 genomes (11, 17, 19), we are just beginning to learn how these lethal population-level phage  
94 defense systems are controlled.

95

96 Bacteria sense their population density through quorum sensing (QS). Based on the  
97 constituency and abundance of bacteria in the environment, a bacterium uses QS to enact gene  
98 expression patterns that promote or discourage participation in coordinated population-level  
99 behaviors (reviewed in (20, 21)). Bacteria assess the local population density and composition  
100 by producing, secreting, and detecting small molecules called auto-inducers (AIs) whose  
101 environmental concentrations are a proxy for bacterial abundance. In *V. cholerae*, QS gene  
102 expression programs for low-cell density (LCD) and high-cell density (HCD) are regulated by the  
103 transcription factors LuxO and HapR, respectively. At LCD, when the environmental  
104 concentrations of AIs are low, LuxO is active and *hapR* mRNA is degraded. As AI concentrations  
105 increase in the environment, a proxy for an increasing population density, LuxO activity is  
106 inhibited via dephosphorylation, driving *hapR* expression and enabling induction of the HCD  
107 gene expression regulon. The dichotomous QS-dependent activities of LuxO and HapR are  
108 primarily responsible for the differential regulation of more than 500 *V. cholerae* genes (22).

109 These population-dependent changes in transcription determine whether *V. cholerae* pursue  
110 behavioral strategies best suited for a solitary or group lifestyle at LCD or HCD.

111  
112 To better understand the contribution of the VSP islands to the evolution of the 7<sup>th</sup> *V. cholerae*  
113 pandemic, we explored if the VSP islands in the El Tor biotype were responsible for some of the  
114 well-known phenotypic differences between strains of the classical and El Tor biotypes. We  
115 report that El Tor's sensitivity to the folate biosynthesis inhibitor SMX is dependent on the VSP-1  
116 encoded Type-II CBASS. This sensitivity results from the spurious activation of DncV and the  
117 subsequent activation of the phospholipase CapV. Furthermore, during these studies we found  
118 that the expression of *dncV* and *capV* are induced at HCD by the *V. cholerae* QS pathway,  
119 consistent with its function as a population-level phage defense mechanism. Our findings  
120 identify both transcriptional and post-transcriptional mechanisms that lead to the deployment  
121 and activation of the El Tor *V. cholerae* CBASS.

122

## 123 **Results**

124 **VSP-1 and -2 do not impact metabolic phenotypes commonly used to distinguish the El Tor  
125 and classical *V. cholerae* biotypes**

126 We examined whether the VSP-1 and VSP-2 islands contributed to phenotypic behaviors  
127 commonly attributed to the El Tor biotype by performing several biotyping assays comparing  
128 classical strain O395 (23) and the El Tor strain C6706str2 (C6706) (24) with those of single VSP  
129 island mutants ( $\Delta$ VSP-1 and  $\Delta$ VSP-2) and a double VSP island mutant ( $\Delta$ VSP1/2). O395 is known  
130 to be deficient in both protease and hemolysin production in comparison to C6706, as

131 demonstrated on casein milk agar and blood agar plates, respectively (4). Simple streaks of  
132 these strains on milk agar and sheep blood agar confirmed differential degradation of casein  
133 and hemolytic activities between O395 and C6706, as indicated by the absence and presence of  
134 a zone of clearing on each medium, respectively (Figs. 1A & 1B). We found that deletion of one  
135 or both VSP islands did not affect either activity as all three mutants phenocopied the parental  
136 C6706 strain (Figs. 1A & 1B). Similarly, classical O395 cannot utilize citrate as a sole carbon  
137 source (25) or grow on MacConkey agar, while C6706 can do both. Again, we found that the VSP  
138 islands do not contribute to these two phenotypes as all three mutants grew comparably to the  
139 parental C6706 strain on these media (Figs. 1C and 1D). Finally, El Tor strains are known to  
140 produce acetoin upon fermentation of glucose while classical strains do not (26). Using the  
141 colorimetric Voges-Proskauer assay to measure acetoin by the generation of a red color, we  
142 found supernatants of C6706 produced a deep red color, indicative of acetoin production, while  
143 classical O395 was weakly pink (Fig. 1E). Production of acetoin was not grossly impacted upon  
144 deletion of either or both VSP islands (Fig. 1E) as these strains also produced a deep red color  
145 like the parental C6706. While casein degradation in milk agar and production of the  
146 fermentative bioproduct acetoin have been linked to QS (4, 27) and the inability of O395 to  
147 perform these functions is likely due, in-part, to its non-functional *hapR* allele (28), we  
148 nonetheless demonstrate the VSP islands do not contribute to these phenotypes in C6706.

149

150 **The VSP-1 and -2 islands do not contribute to El Tor C6706 colonization in an infant mouse**  
151 **model**

152 Subtle differences in the sequences of the virulence gene alleles *ctxB* and *tcpA* between strains  
153 of the El Tor and classical biotypes have been used for biotyping novel *V. cholerae* isolates (4).  
154 The classical biotype is also more permissive in its in vitro expression of the *V. cholerae*  
155 virulence regulon compared to the El Tor biotype (29), which anecdotally causes less severe  
156 cholera in humans (30). To determine whether the VSP islands collectively contribute to in vivo  
157 colonization we performed a competition infection between C6706 and  $\Delta$ VSP-1/2 in the infant  
158 mouse model of cholera. Despite the previous attribution of *dncV*, the CBASS cGAMP synthase  
159 located in VSP-1, to colonization (18), we found no competitive defect in the ability of the  
160 double VSP island mutant to colonize the infant mouse intestinal tract (Fig. 1F). The discrepancy  
161 between this finding and *Davies et al.* 2012 may be attributed to unknown epistatic  
162 relationships between *dncV* and other VSP encoded genes which obscure this colonization  
163 defect in our study, genetic differences between laboratory lineages of C6706 (31), or specific  
164 conditions not replicated in our study. Nevertheless, our result suggests that the collective  
165 impact of the VSP islands on colonization in the infant mouse model of cholera is negligible.

166

167 **VSP-1 increases sensitivity to sulfamethoxazole**

168 In addition to different metabolic and virulence characteristics, different susceptibilities to  
169 antibiotics have also been observed between classical and El Tor strains. One such antibiotic is  
170 the cationic antimicrobial peptide polymyxin B, which disrupts the outer membrane of Gram-  
171 negative bacteria. Indeed, as previously observed in pandemic *V. cholerae* biotypes (32, 33), we  
172 found that classical O395 was more sensitive to polymyxin B than El Tor C6706 with half  
173 maximal inhibitory concentrations ( $IC_{50}$ ) of 0.6 and 18.4  $\mu$ g/mL, respectively (Fig. S1 , Table S1).

174 However, deletion of VSP-1, VSP-2, or both islands did not grossly impact El Tor's susceptibility  
175 to polymyxin B (Fig. S1, Table S1) demonstrating the VSP islands do not contribute to this  
176 biotype specific phenotype.

177

178 In contrast to polymyxin B, strains of the El Tor biotype have been shown to exhibit greater  
179 sensitivity to sulfamethoxazole (SMX) than those of the classical biotype (5). SMX impairs folate  
180 biosynthesis by inhibiting the activity of dihydropteroate synthase. After treating our strains  
181 with a concentration gradient of SMX and measuring culture optical densities after 24 hours we  
182 found C6706 was profoundly more sensitive to SMX ( $IC_{50}$  36.5  $\mu$ g/mL) than classical O395 ( $IC_{50}$   
183 230.7  $\mu$ g/mL) (Figs. 2A & S2A, Table S1). Surprisingly, both  $\Delta$ VSP-1 and  $\Delta$ VSP-1/2 phenocopied  
184 O395's SMX resistance while the  $\Delta$ VSP-2 mutant retained the parental C6706 SMX sensitivity  
185 (Figs. 2A & S2A, Table S1). Hypothesizing SMX sensitivity could be attributed to VSP-1, we  
186 reintroduced VSP-1 into the  $\Delta$ VSP-1/2 mutant on a single copy cosmid (pVSP-1) and found this  
187 was sufficient to restore SMX sensitivity (Figs. 2B & S2B). Additionally, provision of pVSP-1 to  
188 both O395 and *Escherichia coli* BL21(DE3) also increased each strain's sensitivity to SMX (Figs.  
189 2B, S2C & S2D). Together, these results demonstrate the disparity in *V. cholerae* biotype specific  
190 sensitivities to SMX is the result of a factor encoded on VSP-1.

191

192 **Sulfamethoxazole sensitivity requires the CBASS genes *dncV* and *capV***

193 The VSP-1 island of *V. cholerae* C6706 contains 12 known or predicted genes (Fig. 2C). To  
194 identify which genes are responsible for SMX sensitivity, we challenged three partial VSP-1  
195 island mutants ( $\Delta$ avcD-vc0176,  $\Delta$ vspR-cap3, and  $\Delta$ vc0182-vc0185) with a gradient of SMX

196 concentrations and found only the  $\Delta vspR\text{-}cap3$  mutant was more resistant to SMX (Figs. 2D &  
197 S2E). The five genes missing in this mutant include the negative transcriptional regulator of  
198 CBASS, *vspR* (18), and the four gene CBASS (*dncV\text{-}cap3*) (11) (Fig. 2C). It was previously shown  
199 that folates are allosteric regulators of DncV which suppress cGAMP synthesis in vitro (34) and  
200 that cGAMP is required for the activation of the lethal phospholipase CapV (10). We therefore  
201 hypothesized that inhibition of folate biosynthesis by SMX could alleviate the folate-dependent  
202 repression of DncV activity and lead to CapV-dependent cell death. In support of this  
203 hypothesis, deletion of either *dncV* or *capV* was sufficient to enhance resistance to SMX in these  
204 conditions while loss of *vspR*, *cap2*, or *cap3* was not (Figs. 2D & S2F).

205

#### 206 **Sulfamethoxazole activates DncV cGAMP synthesis**

207 It was previously reported that the addition of sulfonamide to *E. coli* strains ectopically  
208 expressing *dncV* from a high-copy plasmid enhanced the catalytic activity of DncV (34). To test  
209 whether SMX treatment might induce cGAMP synthesis by DncV in its native cellular and  
210 genetic contexts, we back-diluted stationary phase cultures of C6706 and  $\Delta capV$  1:1,000 in  
211 fresh medium, allowed them to recover for approximately one hour, introduced 100  $\mu$ g/mL SMX  
212 or a DMSO control, and measured culture optical density over the course of six hours.  
213 Concurrent with monitoring culture density, we also measured the intracellular concentration of  
214 cGAMP using UPLC-MS/MS, but this measurement was only performed in the  $\Delta capV$  cultures  
215 where detectable levels of cGAMP can accumulate without inducing CapV-dependent cell lysis  
216 (10). Surprisingly, C6706 cultures treated with SMX only exhibited a growth defect after two  
217 hours of exposure to the antibiotic (Fig. 3A). This growth defect is a consequence of CapV

218 activity as there was no difference in growth between  $\Delta capV$  cultures treated with and without  
219 SMX (Fig. 3A). Similarly, cGAMP was only found in  $\Delta capV$  cultures challenged with SMX and was  
220 not detected until more than two hours after its addition (Fig. 3A). While these results  
221 demonstrate that SMX stimulates DncV synthesis of cGAMP in its native environment, they also  
222 reveal a profound delay exists between introduction of the antibiotic and evidence of DncV  
223 activity under these experimental conditions.

224

## 225 **QS contributes to CBASS-dependent SMX sensitivity**

226 Hypothesizing the two-hour delay in SMX-dependent growth inhibition and cGAMP synthesis  
227 (Fig. 3A) was an indication of CBASS regulation by QS, we challenged QS mutants locked in LCD  
228 or HCD gene expression with 100  $\mu$ g/mL SMX or a DMSO control and monitored culture  
229 densities over time. Because LCD QS mutants have a propensity to form biofilms, which could  
230 interfere with measuring optical density, we utilized QS mutants derived from the biofilm-null  
231 C6706  $\Delta vpsL$  background (35). Importantly, there is no difference between C6706 and  $\Delta vpsL$   
232 when challenged with SMX or DMSO in these conditions (Fig. S3). As previously seen for C6706  
233 (Fig. 3A), the  $\Delta vpsL$  cultures with an intact QS system experienced a similar two-hour delay in  
234 growth inhibition in response to SMX (Fig. 3B). In agreement with our hypothesis that QS  
235 induces CBASS, the LCD-locked  $\Delta vpsL\Delta hapR$  strain was tolerant of SMX (Figs. 3C) while the HCD-  
236 locked  $\Delta vpsL\Delta luxO$  was hypersensitive to SMX with an abbreviated temporal delay in growth  
237 inhibition (Fig. 3D). Together, these results support the argument that QS contributes to the  
238 regulation of CBASS.

239

240 **QS regulates transcription of the *V. cholerae* CBASS operon**

241 To determine if QS regulation of CBASS was at the level of transcription induction, we first  
242 monitored the abundance of *capV* and *dncV* transcripts in cultures of *V. cholerae* C6706 over  
243 time using RT-qPCR. Three hours following inoculation and corresponding with  $\sim 0.6$  OD<sub>600</sub>, a  
244 culture density consistent with the transition from LCD to HCD (36), the abundance of each  
245 transcript abruptly increased  $\sim 8$ -fold relative to their initial levels and remained high for the  
246 duration of the experiment (Fig. 4A). Notably, the increased abundance of both *capV* and *dncV*  
247 transcripts three hours post inoculation precedes both the SMX-dependent detection of cGAMP  
248 in the  $\Delta capV$  mutant and growth inhibition by SMX of quorum fluent strains in previous  
249 experiments (Figs. 3A, 3B, S3A).

250

251 To confirm the observed increase in *capV* and *dncV* transcripts were the result of HCD gene  
252 expression we measured their abundance in a strain of C6706 ( $\Delta csqA\Delta luxS$ ) (37) which is  
253 incapable of producing the two primary *V. cholerae* AIs, CAI-2 and AI-1. In monoculture,  
254  $\Delta csqA\Delta luxS$  is locked in LCD gene expression, regardless of the population density, but can be  
255 converted to HCD gene expression by the introduction of exogenous AIs. Using RT-qPCR, we  
256 found when  $\Delta csqA\Delta luxS$  was grown in the presence of exogenous AIs there was at least a 6-fold  
257 greater abundance of *capV* and *dncV* transcripts than when grown in their absence (Fig. 4B). As  
258 a control, the abundance of *hapR* transcript also increased upon AI addition indicating the  
259 cultures had been converted to HCD gene expression (Fig. 4B).

260

261 To better understand how QS was regulating the abundance of CBASS transcripts, we  
262 constructed a luminescent transcriptional plasmid reporter containing a 913 nt region 5' of the  
263 *capV* translational start site with the CBASS promoter (pP<sub>CBASS</sub>::*lux*) and measured luminescence  
264 generated by biofilm-null  $\Delta vpsL$  QS mutants at LCD and HCD. The HCD-locked strain,  $\Delta vpsL\Delta luxO$   
265 was the most luminescent at both densities whereas the LCD-locked strain,  $\Delta vpsL\Delta hapR$ , was  
266 sparingly luminescent regardless of the culture density (Fig. 4C). The quorum fluent strain,  
267  $\Delta vpsL$ , resembled  $\Delta vpsL\Delta hapR$  at LCD and  $\Delta vpsL\Delta luxO$  at HCD (Fig. 4C). These results indicated  
268 that transcription initiation of the CBASS promoter is positively regulated at HCD.

269

270 The transcription factor primarily responsible for HCD gene expression in *V. cholerae* is HapR  
271 (28). To determine if HapR could enhance expression of the CBASS promoter independent of  
272 additional *V. cholerae* genes, we measured the luminescent output of pP<sub>CBASS</sub>::*lux* in a  
273 heterologous *E. coli* host and provided *hapR* in trans on an inducible plasmid (pHapR). The  
274 relative luminescence of *E. coli* cultures maintaining pHapR were significantly greater than the  
275 vector control following introduction of the inducer (Fig. 4D). In total, our data indicate CBASS is  
276 expressed as part of the HCD regulon in *V. cholerae* C6706 and this expression is induced by  
277 HapR.

278

279 **HapR-dependent induction of CBASS transcription contributes to phage defense**  
280 QS induction of the CBASS operon suggests that this system would exhibit higher levels of phage  
281 defense at HCD. However, we have not identified a condition in which the *V. cholerae* CBASS  
282 operon protects against infection by the three major *V. cholerae* lytic phage ICP-1, ICP-2, and

283 ICP-3 (38). Thus, we are unable to test this prediction in *V. cholerae* expressing CBASS from its  
284 native genomic context. To circumvent this challenge, we examined if the *V. cholerae* CBASS  
285 operon provided phage defense when expressed from a low-copy cosmid (pVSP-1) in *E. coli* to  
286 the lytic phage T2 in shaking liquid cultures. In these conditions, pVSP-1 alone provided only  
287 minimal enhancement of *E. coli* growth when challenged with T2 at low multiplicities of  
288 infection (MOIs) (Fig. 5A, S4). However, HapR expression substantially enhanced protection by  
289 pVSP-1 to T2 phage infection, demonstrating that QS enhancement of CBASS expression leads  
290 to greater phage defense (Fig. 5A, S4).

291

## 292 **Discussion**

293 The earliest strains of the El Tor biotype were first encountered during the period of 1897 –  
294 1938 and considered non-pathogenic enteric commensals (3). Through genotypic analysis of  
295 early and modern El Tor strains, Hu *et al.* (3) traced the evolutionary lineage of the El Tor biotype  
296 from non-pathogenic commensal to pandemic scourge in six phases. While these phases  
297 include the predictable acquisition of key virulence factors including *tcpA*, *toxT*, and cholera  
298 toxin, the 5<sup>th</sup> stage (1925-1954) is primarily defined by El Tor's acquisition of VSP-1 and -2 from  
299 unknown origins. While it has been hypothesized that acquisition of VSP-1 and -2 potentiated El  
300 Tor's pandemicity and rise to global dominance in the 7<sup>th</sup> Pandemic, we are just beginning to  
301 understand their utility and the functions they encode.

302

303 Our analyses show that VSP-1 and -2 do not contribute to previously identified metabolic  
304 differences between El Tor and Classical biotypes nor do they collectively influence colonization

305 in an infant mouse infection model. Rather, we demonstrate that the increased sensitivity to the  
306 antibiotic SMX in the model El Tor strain C6706 is due to the spurious activation of the abortive  
307 infection anti-phage Type-II CBASS encoded on VSP-1. Upon exposure to SMX, inhibition of  
308 folate biosynthesis de-represses DncV which leads to the synthesis of cGAMP (Fig. 5B). This  
309 increase of intracellular cGAMP allosterically activates the phospholipase CapV leading to the  
310 degradation of bacterial membranes and cell death (10) (Fig. 5B). We note that a recent study  
311 independently reached the same conclusion finding that the CBASS system of *V. cholerae* strain  
312 N16961 drove sensitivity to SMX (39). N16961 is a natural locked LCD mutant of *V. cholerae* with  
313 a non-functional *hapR*, and thus the role of QS in CBASS activity could not be observed in this  
314 study. In response to increased usage of SMX to treat cholera infections, SMX resistance has  
315 been observed in 79% of O1/O139 isolates (40). However, such resistance is not due to the loss  
316 of CBASS function but rather the acquisition of other resistance mechanisms like the SXT  
317 integrative conjugative element (41, 42). The fact that El Tor strains retain CBASS function and  
318 VSP-1 while acquiring resistance to SMX via alternate mechanisms argues that the VSP-1 island  
319 continues to play an important role in the fitness of circulating El Tor biotype strains. One such  
320 role could be enhanced resistance to phage predation which has been hypothesized to  
321 contributed to the global rise of the El Tor biotype and displacement of the classical biotype  
322 prior to the 7<sup>th</sup> pandemic (43).

323  
324 The link between SMX exposure and the activation of the VSP-1 CBASS is likely the result of non-  
325 competitive inhibition of DncV by folate molecules. The x-ray crystal structure of DncV  
326 unexpectedly revealed a molecule of 5-methyl-tetrahydrate folate bound on the opposite face

327 of the active site (34). Further study revealed that the in vitro cyclase activity of purified DncV  
328 was inhibited by the addition of various folate molecules (34). Additionally, introduction of the  
329 folate biosynthesis inhibitors sulfonamide and trimethoprim to *E. coli* expressing recombinant  
330 DncV led to an increase in the intracellular concentration of cGAMP relative to untreated cells  
331 (34). DncV belongs to the CD-NTase family of cyclic oligo-nucleotide synthases, which are often  
332 allosterically regulated (reviewed in (44)). For example, metazoan cGAS only synthesizes 2'3'  
333 cyclic GMP-AMP when bound to dsDNA as this is a biological signal for viral invasion or genome  
334 instability (45, 46) while the homolog cGLR1 from *Drosophila melanogaster* responds to dsRNA  
335 (47). Activation of DncV in *V. cholerae* by SMX indicates folates likely allosterically inhibit this  
336 CD-NTase in its native host.

337  
338 Given that DncV initiates an abortive infection program (48), and its activity is inhibited by  
339 folates (34), we hypothesize that disruption of folate metabolism is a cellular indication of  
340 phage infection. In support of this idea, phage often encode nucleotide biosynthetic enzymes  
341 and extensively remodel cellular nucleotide pools, which can in turn alter folate metabolism.  
342 For example, the bacteriophage T4 encoded protein 55.1 forms a complex with *E. coli* FolD, a  
343 bifunctional enzyme that catalyzes interconversion of 5,10-methylene-tetrahydrofolate and 10-  
344 formyl-tetrahydrofolate, and induces hypersensitivity to trimethoprim (49). Additionally, the T4  
345 strain, T4D, has been shown to shift the metabolism of folate compounds during infection in *E.*  
346 *coli* (reviewed in (50)). T4 phage have also been shown in numerous studies to be susceptible to  
347 CBASS anti-phage activities (11–13). Our results support a model (Fig. 5B) that depletion of  
348 folates upon phage infection is the activation signal for DncV to initiate abortive infection,

349 though this remains to be formally tested. It is also unclear whether folates facilitate or  
350 antagonize the dichotomous activities of Cap2 and Cap3 which enhance and suppress DncV  
351 activity, respectively, through post-translation modification of its C-terminus (12, 13). Under the  
352 conditions we tested, activation by folate depletion is indifferent to the post-translational  
353 modification state of DncV as loss of either *cap2* or *cap3* did not substantially affect SMX  
354 sensitivity (Figs. 2D & S2F).

355

356 Our studies of SMX activation of DncV showed a consistent delay in cell killing, which we  
357 determined is due to the QS-dependent transcription of CBASS by the HCD transcriptional  
358 regulator HapR (Fig. 5B). In agreement with this, RNA-seq analysis of *V. cholerae* C6706  
359 demonstrated that CBASS transcripts were significantly more abundant at HCD than LCD (22).  
360 QS regulation appears to be another mechanism to restrict the activity of the VSP-1 CBASS  
361 system to the most appropriate conditions, thereby preventing spurious activation of DncV and  
362 CapV and unnecessary cell death. Identification of the VSP-1 encoded transcription factor VspR  
363 (Fig. 2C, 5B) was pivotal to the discovery of DncV (18). ChIP analysis revealed VspR was  
364 associated with DNA sequences found within the CBASS locus and *vspR* mutants contained a  
365 greater abundance of CBASS gene transcripts, implicating it as a negative transcriptional  
366 regulator of CBASS (18). Contrary to our expectation, under our experimental conditions *vspR*  
367 did not contribute to CBASS-dependent SMX sensitivity (Fig. 2D & S2F). If and how VspR and QS  
368 regulation of CBASS overlap remains to be explored.

369

370 The role of QS in defense against phage has been previously described (reviewed in (51)) and  
371 some notable examples include the regulation of phage receptor abundance in *E. coli* (52) as  
372 well as haemagglutinin protease production in El Tor *V. cholerae* (53), CRISPR-Cas expression in  
373 *Pseudomonas aeruginosa* (54), and the *hapR* independent HCD-regulation of the El Tor VSP-II  
374 encoded *ddmABC* anti-phage and plasmid defense system (15). From an ecological perspective,  
375 reserving the expression and activity of the VSP-1 CBASS to situations where El Tor *V. cholerae*  
376 would find itself in an environment densely populated with kin fits with its biological function of  
377 preventing phage infection by abortive replication. HCD populations are environments where  
378 phage will be the most prevalent and bacteria at greater risk of infection. At LCD, when  
379 neighbors are scarce, abortive infection is unlikely to be an evolutionarily advantageous strategy  
380 and infected cells may instead rely on non-lethal phage defense mechanisms. Though this  
381 remains to be formally tested, one scenario in which El Tor *Vibrio cholerae* defends against  
382 phage could be a reliance of the non-lethal depletion of nucleotides by the *avcID* system (8, 9)  
383 at LCD and the CBASS system at HCD, both of which are encoded in VSP-1. Although the  
384 molecular mechanism of CBASS are now well characterized (55), the regulation of such systems  
385 and their contribution to bacterial evolution and environmental adaptation is just beginning to  
386 be described. CBASS are widely conserved in bacteria (19) and whether QS regulation of such  
387 systems is commonplace should be further investigated.

388

389 **References**

390 1. Clemens JD, Nair GB, Ahmed T, Qadri F, Holmgren J. 2017. Cholera. Lancet (London,  
391 England) 390:1539–1549.  
392 2. Siddique AK, Cash R. 2014. Cholera outbreaks in the classical biotype era. Curr Top  
393 Microbiol Immunol 379:1–16.

394 3. Hu D, Liu B, Feng L, Ding P, Guo X, Wang M, Cao B, Reeves PR, Wang L. 2016. Origins of  
395 the current seventh cholera pandemic. *Proc Natl Acad Sci U S A* 113:E7730–E7739.

396 4. Son MS, Taylor RK. 2011. Genetic Screens and Biochemical Assays to Characterize *Vibrio*  
397 *cholerae* O1 Biotypes: Classical and El Tor. *Curr Protoc Microbiol* 22A:6A.2.1-6A.2.17.

398 5. Northrup RS, Doyle MA, Feeley JC. 1972. In vitro susceptibility of El Tor and classical  
399 *Vibrio cholerae* strains to trimethoprim and sulfamethoxazole. *Antimicrob Agents*  
400 *Chemother* 1:310–4.

401 6. Dziejman M, Balon E, Boyd D, Fraser CM, Heidelberg JF, Mekalanos JJ. 2002. Comparative  
402 genomic analysis of *Vibrio cholerae*: Genes that correlate with cholera endemic and  
403 pandemic disease. *Proc Natl Acad Sci U S A* 99:1556–1561.

404 7. O’Shea YA, Finn S, Reen FJ, Morrissey JP, O’Gara F, Boyd EF. 2004. The *Vibrio* seventh  
405 pandemic island-II is a 26.9 kb genomic island present in *Vibrio cholerae* El Tor and O139  
406 serogroup isolates that shows homology to a 43.4 kb genomic island in *V. vulnificus*.  
407 *Microbiology* 150:4053–4063.

408 8. Hsueh BY, Severin GB, Elg CA, Waldron EJ, Kant A, Wessel AJ, Dover JA, Rhoades CR,  
409 Ridenhour BJ, Parent KN, Neiditch MB, Ravi J, Top EM, Waters CM. 2022. Phage defence  
410 by deaminase-mediated depletion of deoxynucleotides in bacteria. *Nat Microbiol*  
411 7:1210–1220.

412 9. Tal N, Millman A, Stokar-Avihail A, Fedorenko T, Leavitt A, Melamed S, Yirmiya E, Avraham  
413 C, Brandis A, Mehlman T, Amitai G, Sorek R. 2022. Bacteria deplete deoxynucleotides to  
414 defend against bacteriophage infection. *Nat Microbiol* 7:1200–1209.

415 10. Severin GB, Ramliden MS, Hawver LA, Wang K, Pell ME, Kieninger A-K, Khataokar A,  
416 O’Hara BJ, Behrmann L V., Neiditch MB, Benning C, Waters CM, Ng W-L. 2018. Direct  
417 activation of a phospholipase by cyclic GMP-AMP in El Tor *Vibrio cholerae*. *Proc Natl Acad  
418 Sci U S A* 115:E6048–E6055.

419 11. Cohen D, Melamed S, Millman A, Shulman G, Oppenheimer-Shaanan Y, Kacen A, Doron S,  
420 Amitai G, Sorek R. 2019. Cyclic GMP-AMP signalling protects bacteria against viral  
421 infection. *Nature* 574:691–695.

422 12. Ledvina HE, Ye Q, Gu Y, Sullivan AE, Quan Y, Lau RK, Zhou H, Corbett KD, Whiteley AT.  
423 2023. An E1–E2 fusion protein primes antiviral immune signalling in bacteria. *Nature*. doi:  
424 10.1038/s41586-022-05647-4

425 13. Jenson JM, Li T, Du F, Ea C-K, Chen ZJ. 2023. Ubiquitin-like Conjugation by Bacterial cGAS  
426 Enhances Anti-phage Defence. *Nature* <https://doi.org/10.1038/s41586-023-05862-7>.

427 14. Jaskólska M, Adams DW, Blokesch M. 2022. Two defence systems eliminate plasmids from  
428 seventh pandemic *Vibrio cholerae*. *Nature* 604:323–329.

429 15. O’Hara BJ, Alam M, Ng W-L. 2022. The *Vibrio cholerae* Seventh Pandemic Islands act in  
430 tandem to defend against a circulating phage. *PLoS Genet* 18:e1010250.

431 16. Murphy SG, Johnson BA, Ledoux CM, Dörr T. 2021. *Vibrio cholerae*’s mysterious Seventh  
432 Pandemic island (VSP-II) encodes novel Zur-regulated zinc starvation genes involved in  
433 chemotaxis and cell congregation. *PLoS Genet* 17:e1009624.

434 17. Whiteley AT, Eaglesham JB, de Oliveira Mann CC, Morehouse BR, Lowey B, Nieminen EA,  
435 Danilchanka O, King DS, Lee ASY, Mekalanos JJ, Kranzusch PJ. 2019. Bacterial cGAS-like  
436 enzymes synthesize diverse nucleotide signals. *Nature* 567:194–199.

437 18. Davies BW, Bogard RW, Young TS, Mekalanos JJ. 2012. Coordinated regulation of

438 accessory genetic elements produces cyclic di-nucleotides for *V. cholerae* virulence. *Cell*  
439 149:358–70.

440 19. Millman A, Melamed S, Amitai G, Sorek R. 2020. Diversity and classification of cyclic-  
441 oligonucleotide-based anti-phage signalling systems. *Nat Microbiol* 5:1608–1615.

442 20. Ng W-L, Bassler BL. 2009. Bacterial quorum-sensing network architectures. *Annu Rev  
443 Genet* 43:197–222.

444 21. Papenfort K, Bassler BL. 2016. Quorum sensing signal-response systems in Gram-negative  
445 bacteria. *Nat Rev Microbiol* 14:576–88.

446 22. Papenfort K, Förstner KU, Cong J-P, Sharma CM, Bassler BL. 2015. Differential RNA-seq of  
447 *Vibrio cholerae* identifies the VqmR small RNA as a regulator of biofilm formation. *Proc  
448 Natl Acad Sci U S A* 112:E766-75.

449 23. Herrington DA, Hall RH, Losonsky G, Mekalanos JJ, Taylor RK, Levine MM. 1988. Toxin,  
450 toxin-coregulated pili, and the *toxR* regulon are essential for *Vibrio cholerae* pathogenesis  
451 in humans. *J Exp Med* 168:1487–92.

452 24. Thelin KH, Taylor RK. 1996. Toxin-coregulated pilus, but not mannose-sensitive  
453 hemagglutinin, is required for colonization by *Vibrio cholerae* O1 El Tor biotype and O139  
454 strains. *Infect Immun* 64:2853–6.

455 25. Brumfield KD, Carignan BM, Ray JN, Jumpre PE, Son MS. 2017. Laboratory Techniques  
456 Used to Maintain and Differentiate Biotypes of *Vibrio cholerae* Clinical and Environmental  
457 Isolates. *J Vis Exp* <https://doi.org/10.3791/55760>.

458 26. Yoon SS, Mekalanos JJ. 2006. 2,3-butanediol synthesis and the emergence of the *Vibrio  
459 cholerae* El Tor biotype. *Infect Immun* 74:6547–56.

460 27. Hawver LA, Giulietti JM, Baleja JD, Ng W-L. 2016. Quorum Sensing Coordinates  
461 Cooperative Expression of Pyruvate Metabolism Genes To Maintain a Sustainable  
462 Environment for Population Stability. *MBio* 7.

463 28. Zhu J, Miller MB, Vance RE, Dziejman M, Bassler BL, Mekalanos JJ. 2002. Quorum-sensing  
464 regulators control virulence gene expression in *Vibrio cholerae*. *Proc Natl Acad Sci U S A*  
465 99:3129–34.

466 29. DiRita VJ, Neely M, Taylor RK, Bruss PM. 1996. Differential expression of the *ToxR* regulon  
467 in classical and E1 Tor biotypes of *Vibrio cholerae* is due to biotype-specific control over  
468 *toxT* expression. *Proc Natl Acad Sci U S A* 93:7991–7995.

469 30. Kaper JB, Morris JG, Levine MM. 1995. Cholera. *Clin Microbiol Rev* 8:48–86.

470 31. Stutzmann S, Blokesch M. 2016. Circulation of a Quorum-Sensing-Impaired Variant of  
471 *Vibrio cholerae* Strain C6706 Masks Important Phenotypes. *mSphere* 1:1–10.

472 32. Hankins J V, Madsen JA, Giles DK, Brodbelt JS, Trent MS. 2012. Amino acid addition to  
473 *Vibrio cholerae* LPS establishes a link between surface remodeling in gram-positive and  
474 gram-negative bacteria. *Proc Natl Acad Sci U S A* 109:8722–7.

475 33. Matson JS, Yoo HJ, Hakansson K, Dirita VJ. 2010. Polymyxin B resistance in El Tor *Vibrio  
476 cholerae* requires lipid acylation catalyzed by *MsbB*. *J Bacteriol* 192:2044–52.

477 34. Zhu D, Wang L, Shang G, Liu X, Zhu J, Lu D, Wang L, Kan B, Zhang J-R, Xiang Y. 2014.  
478 Structural biochemistry of a *Vibrio cholerae* dinucleotide cyclase reveals cyclase activity  
479 regulation by folates. *Mol Cell* 55:931–937.

480 35. Waters CM, Lu W, Rabinowitz JD, Bassler BL. 2008. Quorum sensing controls biofilm  
481 formation in *Vibrio cholerae* through modulation of cyclic di-GMP levels and repression

482 of vpsT. *J Bacteriol* 190:2527–36.

483 36. Miller MB, Skorupski K, Lenz DH, Taylor RK, Bassler BL. 2002. Parallel quorum sensing  
484 systems converge to regulate virulence in *Vibrio cholerae*. *Cell* 110:303–14.

485 37. Hammer BK, Bassler BL. 2007. Regulatory small RNAs circumvent the conventional  
486 quorum sensing pathway in pandemic *Vibrio cholerae*. *Proc Natl Acad Sci U S A*  
487 104:11145–9.

488 38. Seed KD, Bodi KL, Kropinski AM, Ackermann H-W, Calderwood SB, Qadri F, Camilli A.  
489 2011. Evidence of a Dominant Lineage of *Vibrio cholerae*-Specific Lytic Bacteriophages  
490 Shed by Cholera Patients over a 10-Year Period in Dhaka, Bangladesh. *MBio* 2:e00334-10.

491 39. Brenzinger S, Airoldi M, Ogunleye AJ, Brochado AR. 2023. The antiphage defense system  
492 CBASS controls resistance and enables killing by antifolate antibiotics in &lt;em&gt;*Vibrio*  
493 *cholerae*&lt;/em&gt; *bioRxiv* 2023.02.27.530311.

494 40. Liu C, Wang Y, Azizian K, Omidi N, Hassan Kaviar V, Kouhsari E, Maleki A. 2022.  
495 Antimicrobial resistance in *Vibrio cholerae* O1/O139 clinical isolates: a systematic review  
496 and meta-analysis. *Expert Rev Anti Infect Ther* 20:1217–1231.

497 41. Wozniak RAF, Fouts DE, Spagnolletti M, Colombo MM, Ceccarelli D, Garriss G, Déry C,  
498 Burrus V, Waldor MK. 2009. Comparative ICE genomics: insights into the evolution of the  
499 SXT/R391 family of ICEs. *PLoS Genet* 5:e1000786.

500 42. Bhotra T, Das MM, Pal BB, Singh D V. 2016. Genomic profile of antibiotic resistant,  
501 classical ctxB positive *Vibrio cholerae* O1 biotype El Tor isolated in 2003 and 2005 from  
502 Puri, India: A retrospective study. *Indian J Med Microbiol* 34:462–470.

503 43. Zahid MSH, Waise Z, Kamruzzaman M, Ghosh AN, Nair GB, Khairul Bashar SAM,  
504 Mekalanos JJ, Faruque SM. 2011. An experimental study of phage mediated bactericidal  
505 selection & emergence of the El Tor *Vibrio cholerae*. *Indian J Med Res* 133:218–24.

506 44. Kranzusch PJ. 2019. cGAS and CD-NTase enzymes: structure, mechanism, and evolution.  
507 *Curr Opin Struct Biol* 59:178–187.

508 45. Gao P, Ascano M, Wu Y, Barchet W, Gaffney BL, Zillinger T, Serganov AA, Liu Y, Jones RA,  
509 Hartmann G, Tuschl T, Patel DJ. 2013. Cyclic [G(2',5')pA(3',5')p] is the metazoan second  
510 messenger produced by DNA-activated cyclic GMP-AMP synthase. *Cell* 153:1094–107.

511 46. Civril F, Deimling T, de Oliveira Mann CC, Ablasser A, Moldt M, Witte G, Hornung V,  
512 Hopfner K-P. 2013. Structural mechanism of cytosolic DNA sensing by cGAS. *Nature*  
513 498:332–7.

514 47. Hartmann R, Justesen J, Sarkar SN, Sen GC, Yee VC. 2003. Crystal structure of the 2'-  
515 specific and double-stranded RNA-activated interferon-induced antiviral protein 2'-5'-  
516 oligoadenylate synthetase. *Mol Cell* 12:1173–85.

517 48. Cohen D, Melamed S, Millman A, Shulman G, Oppenheimer-Shaanan Y, Kacen A, Doron S,  
518 Amitai G, Sorek R. 2019. Cyclic GMP-AMP signalling protects bacteria against viral  
519 infection. *Nature* 574:691–695.

520 49. Mattenberger Y, Mattson S, Métrailler J, Silva F, Belin D. 2011. 55.1, a gene of unknown  
521 function of phage T4, impacts on *Escherichia coli* folate metabolism and blocks DNA  
522 repair by the NER. *Mol Microbiol* 82:1406–21.

523 50. Green JM, Matthews RG. 2007. Folate Biosynthesis, Reduction, and Polyglutamylation  
524 and the Interconversion of Folate Derivatives. *EcoSal Plus* 2.

525 51. Wang Y, Dai J, Wang X, Wang Y, Tang F. 2022. Mechanisms of interactions between

526 bacteria and bacteriophage mediate by quorum sensing systems. *Appl Microbiol*  
527 *Biotechnol* 106:2299–2310.

528 52. Høyland-Kroghsbo NM, Maerkedahl RB, Svenningsen S Lo. 2013. A quorum-sensing-  
529 induced bacteriophage defense mechanism. *MBio* 4:e00362-12.

530 53. Hoque MM, Naser I Bin, Bari SMN, Zhu J, Mekalanos JJ, Faruque SM. 2016. Quorum  
531 Regulated Resistance of *Vibrio cholerae* against Environmental Bacteriophages. *Sci Rep*  
532 6:37956.

533 54. Høyland-Kroghsbo NM, Paczkowski J, Mukherjee S, Broniewski J, Westra E, Bondy-  
534 Denomy J, Bassler BL. 2017. Quorum sensing controls the *Pseudomonas aeruginosa*  
535 CRISPR-Cas adaptive immune system. *Proc Natl Acad Sci U S A* 114:131–135.

536 55. Duncan-Lowey B, Kranzusch PJ. 2022. CBASS phage defense and evolution of antiviral  
537 nucleotide signaling. *Curr Opin Immunol* 74:156–163.

538 56. Skorupski K, Taylor RK. 1996. Positive selection vectors for allelic exchange. *Gene* 169:47–  
539 52.

540 57. Lenz DH, Miller MB, Zhu J, Kulkarni R V, Bassler BL. 2005. CsrA and three redundant small  
541 RNAs regulate quorum sensing in *Vibrio cholerae*. *Mol Microbiol* 58:1186–202.

542 58. Gerhardt P, Murray R. E, Wood WA, Krieg NR. 1994. *Methods for General and Molecular*  
543 *Bacteriology*, 1st ed. American Society for Microbiology, Washington, D. C.

544 59. Van Alst AJ, DiRita VJ. 2020. Aerobic Metabolism in *Vibrio cholerae* Is Required for  
545 Population Expansion during Infection. *MBio* 11.

546 60. Anthouard R, DiRita VJ. 2013. Small-Molecule Inhibitors of *toxT* Expression in *Vibrio*  
547 *cholerae*. *MBio* 4.

548 61. Massie JP, Reynolds EL, Koestler BJ, Cong J-P, Agostoni M, Waters CM. 2012.  
549 Quantification of high-specificity cyclic diguanylate signaling. *Proc Natl Acad Sci*  
550 109:12746–12751.

551 62. Dunn AK, Millikan DS, Adin DM, Bose JL, Stabb E V. 2006. New rfp- and pES213-derived  
552 tools for analyzing symbiotic *Vibrio fischeri* reveal patterns of infection and lux expression  
553 in situ. *Appl Environ Microbiol* 72:802–10.

554 63. Svenningsen SL, Waters CM, Bassler BL. 2008. A negative feedback loop involving small  
555 RNAs accelerates *Vibrio cholerae*'s transition out of quorum-sensing mode. *Genes Dev*  
556 22:226–38.

557 64. Friedman AM, Long SR, Brown SE, Buikema WJ, Ausubel FM. 1982. Construction of a  
558 broad host range cosmid cloning vector and its use in the genetic analysis of *Rhizobium*  
559 mutants. *Gene* 18:289–96.

560

561 **Materials and Methods**

562 **Growth conditions and media:**

563 All strains of *V. cholerae* and *E. coli* were grown in LB broth-Miller media (NEOGEN) at  
564 35° C with aeration, unless otherwise stated. When noted, antibiotic selection was utilized at  
565 the following concentrations: streptomycin (50 µg/mL), chloramphenicol (10 µg/mL when used  
566 alone or 5 µg/mL when used with another antibiotic), kanamycin (100 µg/mL when used alone;  
567 50 µg/mL when used with another antibiotic) and tetracycline (5 µg/mL). IPTG was used at 6.25-  
568 10 µM as indicated. *E. coli* BW29427, a diaminopimelic acid (DAP) auxotroph, was additionally  
569 supplemented with 300 µg/mL DAP and used for the conjugative transfer of vectors and  
570 cosmids to all *V. cholerae* strains presented in this work.

571

572 **Cloning and strain construction:**

573 All gene deletions from the *V. cholerae* genome were performed using the vector  
574 pKAS32 (56). Deletion constructs were cloned using a three-piece Gibson Assembly composed  
575 of ~1 kb homologous sequences both 5' and 3' of the genomic region to be removed and linear  
576 pKAS32 double digested with KpnI and SacI. Mutants were obtained through allelic exchange  
577 (56) and verified by Sanger sequencing. All mutants utilized in this study were complete  
578 deletions of the genomic regions of interest except for  $\Delta vspR$  where the *vspR* codons 1, 2, and 6  
579 where all mutated into stop codons. The pP<sub>CBASS</sub>::*lux* plasmid was generated by amplification of  
580 913 n.t. upstream of *capV* and Gibson assembly into BamHI/Spel digested pBBR-lux (57) using  
581 the primers Lux\_CBASSpr\_FW and Lux\_CBASSpr\_RV, 5'.

582

583 **Metabolic Growth Assays**

584 Using an inoculating loop, overnight cultures were applied as a single streak on the  
585 surface of agar plates and incubated at 35° C for 24 h. Images were taken of plates using an  
586 iPhone. For the casein hydrolysis protease assay, milk agar plates were prepared according to (4)  
587 and contained 20.0 g/L dry skim milk and 9.2 g/L brain-heart infusion and 15 g/L agar. Blood  
588 agar plates were prepared according to (58) using Mueller Hinton Broth in 1.5% agar with 5%  
589 sheep blood. Citrate minimal medium agar was prepared according to (4). For comparing  
590 growth on MacConkey agar, an overnight culture of each strain was normalized to an OD<sub>600</sub> of  
591 0.5 and serial diluted ten-fold in PBS to 10<sup>-7</sup>. 2.5 µl of each dilution was plated on both LB and  
592 MacConkey agar plates and incubated ~16 h at 35° C and imaged with an iPhone. For the Voges-  
593 Proskauer (VP) Assay, each strain was inoculated in 3 mL of Methyl Red - Voges-Proskauer (MR-  
594 VP) broth medium (4) from a plate and incubated overnight. Then, 130 µL of 5% (w/v) α-  
595 naphthol and 43 µl of 1M potassium hydroxide was added to 1mL aliquots of the overnight  
596 cultures and allowed color to develop over 48 h at room temperature.

597

598 **Infant Mouse Competition Assay**

599 Infant mice were infected as described previously (59, 60). Briefly, three- to five- day old  
600 CD-1 neonate mice (Charles River, Wilmington, MA) were orogastrically inoculated with  
601 approximately 10<sup>6</sup> total CFU 2 h after separation from dam mice.  $\Delta$ VSP-1/2 was co-inoculated  
602 1:1 with a  $\Delta$ lacZ C6706str2 strain to allow for differentiation by blue-white screening upon  
603 recovery. Mice were maintained at 30°C until euthanasia 20 h post inoculation. To enumerate *V.*  
604 *cholerae* CFU, intestinal segments (small intestine and the large intestine plus cecum) were

605 homogenized, serially diluted, and plated on LB + 0.1 mg/mL streptomycin, 0.08 mg/mL 5-  
606 bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside (X-Gal). Blue and white colony counts were  
607 used to determine the competitive index (C.I.) for  $\Delta$ VSP-1/2 using the following equation: C.I. =  
608 (CFU  $\Delta$ VSP-1/2<sub>intestine</sub> / CFU  $\Delta$ lacZ<sub>intestine</sub>)/(CFU  $\Delta$ VSP-1/2<sub>inoculum</sub> / CFU  $\Delta$ lacZ<sub>inoculum</sub>). The fitness of  
609 the  $\Delta$ lacZ strain was previously shown to have no colonization defect relative to the parental  
610 C6706str2 (59). All animal experiments in this study were approved by the Institutional Animal  
611 Care and Use Committee at Michigan State University.

612

613 **Polymyxin B IC<sub>50</sub>**

614 For the polymyxin B resistance assay, 2 mL LB cultures were incubated for 16 h at 35° C  
615 with aeration. Cultures were then diluted 1:100 in fresh LB, aliquoted into 96-well plates  
616 (COSTAR), and challenged with a four-fold serial dilution of polymyxin B (Sigma) from 55.5  
617  $\mu$ g/mL to 0.014  $\mu$ g/mL. Plates were incubated for 20 h without aeration at 35° C and the culture  
618 absorbance was measured at 600 nm using an Envision 2105 Multimode Plate Reader (Perkin-  
619 Elmer) and % growth for each biological replicate was calculated by dividing the absorbance 600  
620 nm of polymyxin B treated wells by the absorbance of the untreated control well. The reported  
621 mean % growth and standard deviation were calculated from three biological replicates for each  
622 polymyxin B concentration. IC<sub>50</sub> were calculated using a non-linear regression analysis  
623 performed using GraphPad Prism version 9.5.0.

624

625 **Sulfamethoxazole IC<sub>50</sub> and Challenges**

626                   Overnight cultures were grown in the presence of streptomycin unless pLAFR derived  
627                   cosmids were being maintained, in which case tetracycline was supplemented in place of  
628                   streptomycin. Sulfamethoxazole (10 mg/mL) stocks were prepared in DMSO, diluted in LB to  
629                   concentrations 15 x greater than the final desired concentration, and multichannel pipetted into  
630                   clear polystyrene 96-well plates (COSTAR) in 10  $\mu$ L aliquots. Overnight cultures were diluted  
631                   1:10,000 in fresh media supplemented with the same antibiotic selection as the overnight  
632                   media. One hundred and forty  $\mu$ L of the diluted cultures were multichannel pipetted into 96-  
633                   well plates preloaded with trimethoprim or sulfamethoxazole. Plates were wrapped in parafilm  
634                   and incubated at 35° C with aeration for 24 h. Culture absorbance was measured at 600 nm  
635                   using an Envision 2105 Multimode Plate Reader (Perkin-Elmer). % growth for each biological  
636                   replicate was calculated by dividing the mean absorbance of technical replicate treatment wells  
637                   (N = 2 to 4) by the mean absorbance of technical replicate untreated control wells (N = 2 to 4).  
638                   The reported mean % growth and standard error mean were calculated from three biological  
639                   replicates for each concentration. IC<sub>50</sub> were calculated using a non-linear regression analysis  
640                   performed using GraphPad Prism version 9.5.0.

641

642                   **Growth curves and cGAMP quantification by UPLC-MS/MS following Sulfamethoxazole  
643                   challenge**

644                   Overnight cultures were started in triplicate from freezer stocks and grown in LB  
645                   supplemented with streptomycin. Cultures were inoculated 1:1,000 in 50 mL fresh media  
646                   containing selection in 125 mL flasks and grown for 15 minutes before being divided equally  
647                   into two sister cultures. Sister cultures were grown for one additional hour before being

648 sampled to assess culture growth by measuring absorbances at 600 nm and CFU enumeration  
649 by serial dilution plating. Immediately following the initial sampling, sister cultures were  
650 challenged with either 100  $\mu$ g/mL SMX or a DMSO vehicle control and further sampling  
651 continued at ~30 minute intervals for the duration of the experiment. We elected to challenge  
652 these strains with 100  $\mu$ g/mL SMX as this was sufficient to induce CBASS dependent SMX  
653 sensitivity in C6706 and below the IC<sub>50</sub> of  $\Delta$ VSP-1 (Figs. 2A, S2A & Table S1), which has an  
654 analogous SMX resistance phenotype to the  $\Delta$ capV strain (Figs. 2D & S2F).

655 For the purposes of measuring intracellular cGAMP additional aliquots of  $\Delta$ capV sister  
656 cultures (+/- 100  $\mu$ g/mL sulfamethoxazole) were removed at all time points during this  
657 experiment and similarly analyzed as previously described (10). One-milliliter culture aliquots  
658 were pelleted at 15k x g in microcentrifuge tubes for 1 minute, supernatants were removed by  
659 aspiration, and pelleted cells were suspended in 200  $\mu$ L of ice-cold extraction buffer  
660 (acetonitrile, methanol, HPLC-grade water, formic acid (2:2:1:0.02, v/v/v/v)), and stored at -20°  
661 C overnight. Extracts were centrifugation at 15k x g for 1 minute, to remove cellular debris, and  
662 the resulting clarified extracts were transferred to new a microcentrifuge tube and dried in a  
663 SpeedVac. Desiccated extracts were dissolved in 100  $\mu$ L of HPLC-grade water and loaded into  
664 glass sample vials for UPLC-MS/MS analysis using an Acquity Ultra Performance LC system  
665 (Waters) coupled with a Quattro Premier XE mass spectrometer (Waters). Chromatography and  
666 multiple reaction monitoring parameters performed as previously described (10). A cGAMP  
667 standard curve was generated using a two-fold serial dilution of cGAMP (Axxora) in HPLC-grade  
668 water spanning 1.9-125 nM. Intracellular concentrations of cGAMP were calculated by dividing

669 the total moles of cGAMP in a sample by the product of the enumerated CFU in each sample  
670 and a standard cell volume of  $6.46 \times 10^{-16}$  L (10, 61).

671

672 **Growth curves of sulfamethoxazole treated quorum sensing and CBASS mutants**

673         Overnight cultures were diluted to an OD<sub>600</sub> of 0.01 in 6 mL fresh LB medium, recovered  
674 for 1h at 37° C with aeration, and split into paired test tubes. Within a pair of cultures, one was  
675 challenged with 100 µg/mL sulfamethoxazole, dissolved in DMSO, while the second culture was  
676 challenged with DMSO vehicle control. Cultures were incubated at 37° C with aeration and the  
677 culture OD<sub>600</sub> was measured at the times presented for the duration of each experiment. The  
678 mean and standard deviation of biological triplicate samples for all strains and treatments is  
679 reported.

680

681 **Time course gene expression using RT-qPCR**

682         Biological duplicate overnight cultures were started from freezer stock in LB and back  
683 diluted 1:10,000 into 250 mL LB in 1 L flasks and grown at 35° C with aeration. Cultures were  
684 sampled 2, 2.5, 3, 4, and 5 h post inoculation in 50, 30, 1, 0.5, and 0.5 mL aliquots, respectively,  
685 and cells were pelleted by centrifugation. Cell pellets were suspended in 1 mL TRIzol™ Reagent  
686 (Thermo Fischer) and RNA was purified following manufacturer's specifications. Following  
687 manufacturer recommendations, 5 µg of RNA was treated with TURBO™ Dnase (Ambion) and  
688 cDNA was generated using SuperScript™ III (Thermo Fischer). SYBR™ Green PCR Master Mix  
689 (Thermo Fischer) was used according to the manufacturer's recommendations in 25 µL reactions  
690 containing 6.25 ng cDNA template (no reverse-transcription controls used 6.25 ng DNase-

691 treated RNA template) and a final primer concentration of 100 nM. qRT-PCRs reactions were  
692 performed in technical duplicate using a StepOnePlus real-time PCR system (Thermo Fisher  
693 Scientific). Gene expression was calculated using  $\Delta CT$  relative to the *gyrA* housekeeping gene  
694 and comparative  $\Delta\Delta CT$  was determined by comparison of each time point to the  $\Delta CT$  of the  
695 initial 2 h sample ( $\sim 0.05$  OD<sub>600</sub>).

696

697 **Gene expression in response to exogenous autoinducers by RT-qPCR**

698 Colonies of  $\Delta csgA\Delta luxS$  *V. cholerae* were inoculated into LB and incubated with aeration  
699 at 30° C for 16 hours. Each culture was then diluted 1:500 – once into fresh LB supplemented  
700 with autoinducers (5  $\mu$ M CAI-1 and 5  $\mu$ M AI-2) and once into fresh LB without autoinducers. These  
701 cultures were incubated with aeration at 30° C for 2 hours, at which point the OD<sub>600</sub>  
702 measurements for all cultures were confirmed to be similar (OD<sub>600</sub> = 0.4-0.45). Cells were lysed  
703 in TRIzol<sup>TM</sup> Reagent (Invitrogen) then RNA was extracted using the Direct-zol RNA Microprep kit  
704 (Zymo Research). RNA was then treated with 0.5  $\mu$ l TURBO<sup>TM</sup> DNase (Invitrogen) at 37° C for 90  
705 minutes, then an additional 0.5  $\mu$ l TURBO<sup>TM</sup> DNase was added and the samples were incubated  
706 for an additional 90 minutes at 37° C. cDNA was synthesized from total RNA using the  
707 SuperScript<sup>TM</sup> III Reverse Transcriptase kit (Invitrogen). For each sample, RT-qPCR was  
708 performed on 50 ng of cDNA using the SYBR<sup>TM</sup> Select Master Mix kit (Applied Biosystems) and  
709 250 nM of each primer. Expression levels were calculated for each target gene by normalizing to  
710 the housekeeping gene *recA*, then the relative fold expression was calculated by comparing the  
711 target gene expression in the presence of autoinducers to the absence of autoinducers and  
712 reported as the mean of measurements obtained from three biological replicates.

713

714 **Luminescent reporter assays**

715 To assess QS induction of CBASS transcription, overnight cultures of  $\Delta vpsL$ ,  $\Delta vpsL\Delta hapR$ , and  
716  $\Delta vpsL\Delta luxO$  (35) containing pP<sub>CBASS</sub>::lux (pKAD1) inoculated from individual colonies (n=3) grown  
717 in LB in glass test tubes were back diluted 1:1,000 in 3 mLs of LB with chloramphenicol and  
718 grown with shaking at 35° C. At two hours, to measure low cell density, and 20 hours, to  
719 measure high cell density, the bioluminescence and OD<sub>600</sub> of 200 mL of each culture was  
720 transferred to a solid black 96-well plate and quantified on an Envision 2105 Multimode Plate  
721 Reader (Perkin-Elmer). Relative light units were determined by dividing the bioluminescence by  
722 the OD<sub>600</sub>, and each was normalized to the mean relative light units of the locked high cell  
723 density  $\Delta vpsL\Delta luxO$  mutant at the corresponding time point.

724

725 **pHapR and pVSP-1 in E coli**

726 Three independent 2 mL overnight cultures of *E. coli* DH10B with pP<sub>CBASS</sub>::lux (pKAD1) with  
727 pVector2 (pEVS141) (62) or pHapR (pSLS13) (63) grown in LB with chloramphenicol (5  $\mu$ g/mL)  
728 and kanamycin (50  $\mu$ g/mL) were back diluted 1:100 in the same media. 150  $\mu$ L of each culture  
729 was placed in a solid black 96-well plate and incubated without shaking at 35° C. After 1.5  
730 hours, HapR production was induced with 6.25  $\mu$ g/mL IPTG, and bioluminescence and OD<sub>600</sub>  
731 were measured on an Envision 2105 Multimode Plate Reader (Perkin-Elmer) hourly.


732

733 **Phage Challenge Assay**

734     Overnight cultures of *E. coli* DH10B with pVector (pLAFR) (64) or pVSP-1 (10) combined with  
735     pVector2 (pEVS141) (62) or pHapR (pSLS13) (63) were grown in 2 mL LB with 50 µg/mL  
736     kanamycin and 5 µg/mL tetracycline overnight at 35° C with shaking. Each culture was back  
737     diluted 1:1,000 in 2 mL of LB with the same antibiotics + 10 µM IPTG and grown 2-3 hours with  
738     shaking at 35° C before addition of T2 phage at the indicated MOI followed by overnight growth  
739     with shaking at 35° C. The OD<sub>600</sub> was measured the following day (~20 hours) on an Envision  
740     2105 Multimode Plate Reader (Perkin-Elmer), and the OD<sub>600</sub> of each culture was normalized to  
741     the uninfected control and reported as percent growth.

742

743 **Figure Legends**




744

745 **Figure 1: The VSP islands do not contribute to common *V. cholerae* biotyping phenotypes**  
746 **or virulence in a murine model of cholera.**

747 Differential biotyping phenotypes between classical O395, El Tor C6706, and C6706 VSP island  
748 mutants ( $\Delta VSP-1$ ,  $\Delta VSP-2$ , and  $\Delta VSP-1/2$ ) demonstrating strain specific (A) proteolysis of  
749 casein on milk agar, (B) hemolytic activity on blood agar, (C) growth on citrate minimal medium  
750 agar, (D) growth on matched LB and MacConkey agar plates, and (E) production of acetoin  
751 detected by Voges-Proskauer Assay. All images are representative of three independent  
752 experimental replicates. (F) In vivo competition between a 1:1 mixture of C6706  $\Delta VSP1/2$  and  
753 C6706  $\Delta lacZ$  in an infant mouse model of cholera. Intestinal colony forming units (CFU) were  
754 enumerated using blue-white screening 20 hours after oral gavage. N = 8 mice and statistical  
755 significance was determined using a one sample *t* test and a hypothetical mean  $\text{Log}_{10}$  C.I. = 0.  
756 The hypothetical mean is represented by a dotted line. The calculated mean  $\text{Log}_{10}$  C.I. is  
757 represented by a solid line. ns = not significant.  
758

759




760

761

762 **Figure 2: VSP-1 encoded CBASS is responsible for *V. cholerae* biotype specific SMX  
763 sensitivity.**

764 24-hour planktonic antibiotic sensitivity assays were performed in a variety of SMX  
765 concentration gradients. Heatmaps (A), (B), and (D) represent relative growth for each strain  
766 calculated using culture optical densities and the equation ( $\text{OD}_{600}$  SMX treatment /  $\text{OD}_{600}$   
767 untreated) and reported as a color-coded mean % of N = 3 biological replicates. The IC<sub>50</sub> for all  
768 strains in (A) are presented in Supplementary Table 1. Scatter plots corresponding to (A) (B) and  
769 (D) are presented in (Figs. S2A-F). (C) Cartoon depiction of the VSP-1 genomic island. Dotted  
770 lines indicate partial VSP-1 truncations. Grey chevrons highlight the four gene VSP-1 CBASS  
771 operon.

772



773


774 **Figure 3: Culture density-dependent sensitivity to SMX reveals quorum sensing regulation**  
 775 **of VSP-1 CBASS.**

776 (A) Growth curves (OD<sub>600</sub>, left y-axis) of WT C6706 and  $\Delta capV$  cultures treated without (+  
 777 DMSO) and with 100  $\mu$ g/mL SMX (+ SMX). Intracellular cGAMP ( $\mu$ M, right y-axis) measured  
 778 by UPLC-MS/MS in the SMX treated and untreated  $\Delta capV$  cultures. Growth curves of (B)  
 779 quorum fluent  $\Delta vpsL$ , (C) LCD-locked  $\Delta vpsL\Delta hapR$ , and (D) HCD-locked  $\Delta vpsL\Delta luxO$  cultures  
 780 treated without (+ DMSO) and with 100  $\mu$ g/mL SMX (+ SMX). Grey arrows indicate addition of  
 781 100  $\mu$ g/mL SMX or DMSO. N = 3 biological replicates and error bars represent standard  
 782 deviation. Statistical significance calculated using an unpaired *t* test with the Holm-Šídák method  
 783 (\*P < 0.05, \*\*P < 0.005, \*\*\*P < 0.0005), n.s. = not significant.

784

785


786



787

788 **Figure 4: QS regulates expression of *V. cholerae* CBASS.**

789 (A) Growth curve (OD<sub>600</sub>, left y-axis, solid line) of *V. cholerae* C6706 and the corresponding  
790 fold-change in transcript abundance (right-axis) of *capV* and *dncV*, relative to the initial 2-hour  
791 time-point, measured using RT-qPCR. N = 2 biological replicates and error bars represent  
792 standard deviation. (B) Relative transcript abundance of *capV*, *dncV*, and *hapR* measured by  
793 qRT-PCR in  $\Delta csqA\Delta luxS$  grown in the presence (+) and absence (-) of exogenous autoinducers  
794 (AIs). N = 3 biological replicates and error bars represent standard error of the mean. (C) %  
795 relative luminescence units of the indicated strains normalized to the mean lum/OD<sub>600</sub> of  
796  $\Delta vpsL\Delta luxO$  maintaining the luminescent transcriptional reporter pP<sub>CBASS</sub>::lux. Population  
797 densities are low-cell density (LCD) and high-cell density (HCD). N = 3 biological replicates  
798 and error bars represent standard deviation. (D) Relative luminescence (lum/OD<sub>600</sub>) of *E. coli*  
799 maintaining the luminescent transcriptional reporter pP<sub>CBASS</sub>::lux and the P<sub>tac</sub> inducible *hapR*  
800 plasmid (pHapR) or a vector control (pVector2) grown in the presence of 6.25  $\mu$ M IPTG. N = 3  
801 biological replicates and error bars represent standard deviation. Statistical significance  
802 calculated using an unpaired t test with the Holm-Šídák method (\*\*P < 0.005, \*\*\*P < 0.0005),  
803 n.s. = not significant.




804 **Figure 5: HapR enhances VSP-1 mediated phage defense in *E. coli***

805 (A) Growth of *E. coli* containing either pHapR induced with 10  $\mu$ M IPTG and pVSP-1 with their  
 806 associated vector controls after overnight growth with T2 phage is shown as a mean percent of  
 807 the uninfected culture from  $N = 3$  biological replicates. Mean % presented numerically and by  
 808 heatmap for each condition. Scatter plot of data presented in (Fig. S4). (B) Model of folate (by  
 809 SMX) and QS (by HapR) regulation of CBASS activity and expression. At HCD, HapR induces  
 810 transcription of the CBASS operon. Inhibition of folate biosynthesis by SMX alleviates the  
 811 folate-dependent non-competitive inhibition of DncV leading to synthesis of cGAMP and  
 812 activation of the phospholipase CapV. CBASS activity ultimately culminates in abortive  
 813 infection that thwarts phage predation by limiting phage replication. Solid arrows and brakes  
 814 indicate regulatory mechanisms that influence CBASS activity addressed in this study. Black  
 815 hatched arrows and brakes indicate mechanisms known to contribute to CBASS activity but were  
 816 not found to significantly contribute to QS or folate mechanisms illuminated in this study. Red  
 817 brake represents a hypothesized phage-dependent disturbance in folates which is sensed by  
 818 DncV to initiate abortive infection by the *V. cholerae* CBASS. Created with BioRender.com.







819

820




**Figure S1: VSP-1 & -2 do not contribute to C6706 resistance to the antimicrobial peptide polymyxin B.**

20-hour planktonic antibiotic sensitivity assay performed using a polymyxin B concentration gradient. % Growth reported as  $(OD_{600} \text{ polymyxin B treated} / OD_{600} \text{ untreated})$  after 20 hours. Dotted line indicates 0% Growth. N = 3 biological replicates for all data points. Error bars represent standard deviation. IC<sub>50</sub> for all strains are presented in Supplementary Table 1.

**A****B****C****D****E****F****Fig. S2**


**Figure S2: Scatter plots showing that VSP-1 encoded CBASS is responsible for *V. cholerae* biotype specific SMX sensitivity.**

(A-F) 24-hour planktonic antibiotic sensitivity assays performed in a variety of SMX concentration gradients. Scatter plots represent are the same data presented in heatmap form in (Figs. 2A, 2B, & 2D). N = 3 biological replicates and error bars represent standard error of the mean. IC<sub>50</sub> for all strains in (A) are presented in Supplementary Table 1.



**Figure S3: Lack of biofilm formation does not alter *V. cholerae* C6706 sensitivity to SMX.**

Growth curves of (A) *V. cholerae* C6706 treated without (+ DMSO) and with 100  $\mu$ g/mL SMX (+ SMX), and C6706 and  $\Delta vpsL$  (B) untreated (+DMSO) and (D) treated (+SMX) with 100  $\mu$ g/mL SMX. Grey arrows indicate addition of 100  $\mu$ g/mL SMX or DMSO, approximately 1-hour after cultures were inoculated. N = 3 biological replicates and error bars represent standard deviation. For the purposes of statistical analysis,  $\Delta vpsL$  data presented in (B) and (C) are also presented in (Fig. 3B). Statistical significance calculated using an unpaired *t* test with the Holm-Šídák method (\* $P < 0.05$ ), n.s. = not significant.



**Figure S4: T2 phage infection graphs.**

Growth of *E. coli* containing either pHapR induced with 10  $\mu$ M IPTG and pVSP-1 with their associated vector controls after overnight growth with T2 phage. Data represent mean percent growth ( $OD_{600}$ ) at the specified MOI calculated relative to control uninfected cultures. N = 3 biological replicates and error bars represent standard deviation. Data presented in heat map form in (Fig. 5A).

**Supplementary Table 1: *V. cholerae* Antibiotic Sensitivity**

Strain	Antibiotic	IC <sub>50</sub> (µg/mL)	R <sup>2</sup>
C6706	Polymyxin B	18.4	0.77
O395	Polymyxin B	0.6	0.85
ΔVSP-1	Polymyxin B	22.1	0.84
ΔVSP-2	Polymyxin B	24.8	0.81
ΔVSP-1/2	Polymyxin B	14.5	0.84
C6706	Sulfamethoxazole	36.5	0.95
O395	Sulfamethoxazole	230.7	0.82
ΔVSP-1	Sulfamethoxazole	184.7	0.85
ΔVSP-2	Sulfamethoxazole	38.0	0.95
ΔVSP-1/2	Sulfamethoxazole	207.2	0.85

IC<sub>50</sub> and R<sup>2</sup> calculated using a non-linear regression analysis of data presented in Fig. S1 (Polymyxin B) and Figs. 2A & S2A (Sulfamethoxazole)

**Supplementary Table 2.** Bacterial strains used in this study.

Strains	Name in this Study	Relevant Characteristics	Source or reference
<b><i>Escherichia coli</i></b>			
BL21(DE3)	<i>E. coli</i> (for SMX treatment, Figs. 2B & S3D)	F- <i>ompT</i> <i>hsdSB(rB -mB +)</i> <i>gal dcm</i> (DE3)	Lab Stock
BW29427	-	RP4-2( <i>TetSkan1360::FRT</i> ), <i>thrB1004</i> , <i>lacZ58(M15)</i> , <i>ΔdapA1341::[erm pir+]</i> , <i>rpsL(strR)</i> , <i>thi-</i> , <i>hsdS-</i> , <i>pro-</i>	Lab Stock
DH10b	<i>E.coli</i> (for luminescence and phage challenge assays, Figs. 4C & 5A)	F- <i>mcrA</i> Δ( <i>mrr-hsdRMS-mcrBC</i> ) Φ80 <i>lacZΔM15 ΔlacX74 recA1 endA1 araD139Δ(ara, leu)7697 galU galK λrpsL nupG</i>	ThermoFisher Scientific
<b><i>Vibrio cholerae</i></b>			
O395	O395	Wild type O1 classical; Sm <sup>R</sup>	DiRita Lab Stock (23)
C6706str2	WT C6706	Wild type O1 El Tor; Sm <sup>R</sup> -Quorum sensing proficient and does not contain the LuxO G333S quorum sensing variant found in some C6706 lineages (14)	Bassler Lab Lineage (8)
CR01	ΔVSP-1	C6706str2 ΔVSP-1	(8)
CR02	ΔVSP-2	C6706str2 ΔVSP-2	(8)
CR03	ΔVSP-1/2	C6706str2 ΔVSP-1/2	(8)
<i>V. cholerae</i> Δ <i>lacZ</i> (VC2338)	Δ <i>lacZ</i>	C6706str2 Δ <i>lacZ</i>	(59)
BYH255	Δ <i>acvD-vc0176</i>	C6706str2 Δ <i>acvD-vc0176</i>	(8)
BYH256	Δ <i>vspR-cap3</i>	C6706str2 Δ <i>vspR-cap3</i>	(8)
BYH257	Δ <i>vc0182-vc0185</i>	C6706str2 Δ <i>vc0182-vc0185</i>	(8)

GS07	$\Delta vspR$	C6706str2 $\Delta vspR$ (not a deletion but a variant with nonsense mutations in codons 1, 2, and 6)	This study
WLN5105	$\Delta capV$	C6706str2 $\Delta capV$	(10)
GS01	$\Delta dncV$	C6706str2 $\Delta dncV$	(10)
WLN5380	$\Delta cap2$	C6706str2 $\Delta cap2$	(10)
WLN5381	$\Delta cap3$	C6706str2 $\Delta cap3$	(10)
CW2034	$\Delta vpsL$	C6706str2 $\Delta vpsL$ biofilm-null	(35)
CW2036	$\Delta vpsL\Delta hapR$	C6706str2 $\Delta vpsL$ biofilm-null LCD-locked	(35)
CW2037	$\Delta vpsL\Delta luxO$	C6706str2 $\Delta vpsL$ biofilm-null HCD-locked	(35)
BH1842	$\Delta csgA\Delta luxS$	C6706str2 $\Delta csgA\Delta luxS$ , LCD-locked with HCD induction by exogenous Als	(37)
<b>Phage</b>			
T2	T2	Wild type	ATCC

**Supplementary Table 3:** Plasmids used in this study

Plasmids	Name in this Study	Relevant characteristics	Source or Reference
pLAFR	pVector	pLAFR cosmid; Tet <sup>r</sup>	(64)
pCCD13	pVSP-1	pLAFR containing VSP-1; Tet <sup>r</sup>	(10)
pBBR-lux	-		(57)
pKAD1	pPCBASS::lux	pBBRlux containing 913bp 5' of <i>capV</i> locus (i.e., CBASS promoter) to regulate luciferase expression	This study
pGBS54	-	pKAS32; Amp <sup>r</sup> containing homologous region for introducing <i>vspR</i> nonsense mutations (creating strain GS07)	This study
pSLS13	pHapR	<i>hapR</i> allele cloned into pEVS143 under P <sub>tac</sub>	(63)
pEVS141	pVector2	Promoterless pEVS143 vector control	(62)

**Supplementary Table 4:** Oligonucleotides used in this study

Name	Primer use	Sequence	Reference
<b>Vector Construction Primers</b>			
DS fwd VC0177 start stop	Construction of pGBS54	TAGTGACGTTCTATGTAGATCAGTCAG AG	This study
DS rev VC0177 start stop	Construction of pGBS54	CTATAGTTCTAGAGGTACCTATGTCCTT TCAAAAAGCAAG	This study
US fwd VC0177 start stop	Construction of pGBS54	ATTCGGGGAGAGCTGTGGTATGAAAG ATGAGTGAATAC	This study
US rev VC0177 start stop	Construction of pGBS54	CTACATAGAACGTCACTAGTATTCTAA TACCAAC	This study
Lux_CBASSpr_FW	PCR P <sub>CBASS</sub> region Rev (913 nt 5' <i>capV</i> into pBBR-lux)	CACCGCGGGTGGCGGGCCGCTCTAGAAA ACGATATATAACCAAAGATCAAG	This study
Lux_CBASSpr_RV	PCR P <sub>CBASS</sub> region Rev (913 nt 5' <i>capV</i> pBBR-lux)	GGATTGAAAACGGAGGTTACCTCTAGT TGCAGGCCGAAAATGGAT	This study
<b>RT-qPCR Primers</b>			
CMW2926	gyrA F, housekeeping gene (Fig. 4A)	TGGCCAGCCAGAGATCAAG	(8)

CMW2927	<i>gyrA</i> R, housekeeping gene (Fig. 4A)	ACCCGCAGCGGTACGA	(8)
<i>capVa</i> F qPCR	<i>capVF</i> (Fig. 4A)	GTGCGCTTGGATAACAACATAC	This study
<i>capVa</i> R qPCR	<i>capVR</i> (Fig. 4A)	TACCGCGGCTAGCTAAATTAC	This study
<i>dncVb</i> F qPCR	<i>dncVF</i> (Fig. 4A)	ACAGACGAGGAGAAGAACAAATC	This study
<i>dncVb</i> R qPCR	<i>dncVR</i> (Fig. 4A)	AGCCTTGGCAATACCCCTTAG	This study
WNTP0011	<i>recA</i> F, housekeeping gene (Fig. 4B)	AATTGTGATGCACTGGCTCGCTC	This study
WNTP0012	<i>recA</i> R, housekeeping gene (Fig. 4B)	CGTCAGTTACGCATTGCTTGCAG	This study
WNTP1492	<i>capVF</i> (Fig. 4B)	CTTGCAGATGGGGATTGGTTGC	This study
WNTP1493	<i>capVR</i> (Fig. 4B)	CCTTGCTTCAGGAAAGTCTGTTGCC	This study
WNTP1494	<i>dncVF</i> (Fig. 4B)	GCACCTTCTGACAGCGAACACG	This study
WNTP1495	<i>dncVR</i> (Fig. 4B)	GTCCAAAAGCGAGGTGTCAATCCC	This study
WNTP0015	<i>hapR</i> F (Fig. 4B)	CGTGACGAAGTTGGCCACTGTTT	This study
WNTP0016	<i>hapR</i> R (Fig. 4B)	TGTTTCTCACACAATTGCCACGC	This study